Premium
Analysis of HLA‐DRB1*0901‐binding HPV‐16 E7 helper T cell epitope †
Author(s) -
Okubo Mitsuo,
Saito Maki,
Inoku Hiroki,
Hirata Ranko,
Yanagisawa Masami,
Takeda Satoru,
Kinoshita Katsuyuki,
Maeda Hiroo
Publication year - 2004
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2003.00171.x
Subject(s) - epitope , human leukocyte antigen , t helper cell , t cell , immunotherapy , immunology , medicine , antigen , cervical carcinoma , virology , microbiology and biotechnology , immune system , biology , cervical cancer , cancer
Aim: This study sought to determine the human papillomavirus (HPV)‐16 E7 epitopes that would be presented by HLA‐DR molecules to CD4‐positive T cells in patients with cervical carcinoma. Methods: HLA‐DR binding assays were performed using HPV‐16 E7‐derived synthetic peptides and, after incubation with these DR‐binding peptides, helper T cell frequencies were analyzed in patients whose HLA and HPV genotypes were confirmed. Results: We determined that the E7d peptide, 61 CDSTLRLCVQSTHVDIRTL 80 E, was bound by HLA‐DRB1*0901. An increased frequency (0.3–2.4%) of type 2 helper T cell responses was found in HLA‐DRB1*0901‐positive patients with cervical dysplasia and carcinoma. We found that when IL‐12 was combined with E7d‐peptide stimulation in vitro, the frequency of type 1 helper T cell responses also increased in patients with carcinoma. Conclusion: Thus HPV‐16 E7d peptide as an HLA‐DRB1*0901‐restricted helper T cell epitope might usefully be incorporated into an understanding of the immunological mechanism and immunotherapy for this disease.